FDA label
What is Descovy used for?
Descovy contains emtricitabine and tenofovir alafenamide. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Descovy lists 2 uses: Treatment of HIV-1 Infection; HIV-1 Pre-Exposure Prophylaxis (PrEP).
Run it in Rivvi
Which 2027 plans near you dropped or restricted Descovy?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Descovy, tablet
Indications and Usage, quoted from the label by Gilead Sciences, Inc. (NDA208215). Cross-references to other label sections are left out.
Treatment of HIV-1 Infection
DESCOVY is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescent patients weighing at least 35 kg.
DESCOVY is indicated for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg to less than 35 kg in combination with other antiretroviral agents, including darunavir and cobicistat but not other protease inhibitors that require a CYP3A inhibitor.
HIV-1 Pre-Exposure Prophylaxis (PrEP)
DESCOVY is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex. Individuals must have a negative HIV-1 test immediately prior to initiating DESCOVY for HIV-1 PrEP.
Limitations of Use:
The indication does not include use of DESCOVY in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
Source: DailyMed label, set id 06f66e98-e6ee-4538-9506-6c1282cc14c1, version 13, effective July 7, 2026. NDC 61958-2002, one of 2 listings for this product.
Questions
What is Descovy used for?
The FDA label for Descovy lists 2 uses: Treatment of HIV-1 Infection; HIV-1 Pre-Exposure Prophylaxis (PrEP).
What drug class is Descovy?
FDA lists emtricitabine and tenofovir alafenamide in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Descovy
- Is Descovy a controlled substance?Federal schedule
- Generic for DescovyFDA Orange Book
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitors listFDA drug class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitors listFDA drug class
- Descovy Medicare Part D coverageBy plan and state
- NDC 61958-2002Descovy NDC record
- NDC 61958-2005Descovy NDC record